Stock listing
Frankfurt:PGO0 Prostatype Genomics AB Aktie
German listing (Frankfurt) of Prostatype Genomics AB · home listing Stockholm:PROGEN
Follow Prostatype Genomics AB into a list and get an email when it puts out news.
Share price · FWB:PGO0
€0.0060 EUR +0.0002 (+3.4%)
Close on Nov 20, 2026
- Day range
- €0.0042 – €0.0060 EURNov 20, 2026
- Market cap
- €933,410 EURAt the close on Nov 20, 2026 · price × 155.6M shares outstanding
- 52-week range
- €0.0040 – €0.1420 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €3 EURMedian day 0 shares · 55 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:PROGEN · Home | 0.089 SEK | 0.000 (-0.4%) | 1,083,923 | 0.092 | 0.092 | 0.085 | 0.090 | Close on Nov 20, 2026 |
| Frankfurt:PGO0 | €0.0060 EUR | +0.0002 (+3.4%) | — | €0.0042 | €0.0060 | €0.0042 | €0.0058 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:PGO0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | +0.0020 | +40.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0050 | -0.0020 | -28.6% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0040 | €0.0070 | €0.0040 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0040 | €0.0070 | €0.0040 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | 0.0000 | 0.0% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0070 | +0.0010 | +16.7% | €0.0040 | €0.0070 | €0.0040 | 0 | |
| €0.0060 | 0.0000 | 0.0% | €0.0040 | €0.0060 | €0.0040 | 0 | |
| €0.0060 | +0.0010 | +20.0% | €0.0040 | €0.0060 | €0.0040 | 0 | |
| €0.0050 | -0.0010 | -16.7% | €0.0040 | €0.0060 | €0.0040 | 0 | |
| €0.0060 | 0.0000 | 0.0% | €0.0040 | €0.0060 | €0.0040 | 0 | |
| €0.0060 | 0.0000 | 0.0% | €0.0040 | €0.0060 | €0.0040 | 0 | |
| €0.0060 | 0.0000 | 0.0% | €0.0040 | €0.0060 | €0.0040 | 0 | |
| €0.0060 | 0.0000 | 0.0% | €0.0040 | €0.0060 | €0.0040 | 0 | |
| €0.0060 | 0.0000 | 0.0% | €0.0040 | €0.0060 | €0.0040 | 0 | |
| €0.0060 | -0.0010 | -14.3% | €0.0050 | €0.0060 | €0.0050 | 0 | |
| €0.0070 | -0.0010 | -12.5% | €0.0050 | €0.0070 | €0.0050 | 0 | |
| €0.0080 | 0.0000 | 0.0% | €0.0050 | €0.0080 | €0.0050 | 0 | |
| €0.0080 | -0.0010 | -11.1% | €0.0050 | €0.0080 | €0.0050 | 0 | |
| €0.0090 | -0.0010 | -10.0% | €0.0060 | €0.0090 | €0.0060 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0070 | €0.0100 | €0.0070 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0070 | €0.0100 | €0.0070 | 0 | |
| €0.0100 | -0.0010 | -9.1% | €0.0070 | €0.0110 | €0.0070 | 0 | |
| €0.0110 | 0.0000 | 0.0% | €0.0070 | €0.0110 | €0.0070 | 0 | |
| €0.0110 | +0.0010 | +10.0% | €0.0070 | €0.0110 | €0.0070 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0070 | €0.0110 | €0.0070 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0070 | €0.0100 | €0.0070 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0080 | €0.0110 | €0.0080 | 0 | |
| €0.0100 | -0.0010 | -9.1% | €0.0080 | €0.0110 | €0.0080 | 0 | |
| €0.0110 | 0.0000 | 0.0% | €0.0080 | €0.0120 | €0.0080 | 0 | |
| €0.0110 | +0.0010 | +10.0% | €0.0070 | €0.0110 | €0.0070 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0070 | €0.0100 | €0.0070 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0070 | €0.0100 | €0.0070 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0070 | €0.0100 | €0.0070 | 0 | |
| €0.0100 | +0.0010 | +11.1% | €0.0060 | €0.0110 | €0.0060 | 0 | |
| €0.0090 | -0.0010 | -10.0% | €0.0060 | €0.0100 | €0.0060 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0070 | €0.0100 | €0.0070 | 0 | |
| €0.0100 | 0.0000 | 0.0% | €0.0070 | €0.0110 | €0.0070 | 0 | |
| €0.0100 | -0.0020 | -16.7% | €0.0080 | €0.0110 | €0.0080 | 0 | |
| €0.0120 | +0.0010 | +9.1% | €0.0070 | €0.0120 | €0.0070 | 0 | |
| €0.0110 | +0.0010 | +10.0% | €0.0070 | €0.0110 | €0.0070 | 0 | |
| €0.0100 | -0.0030 | -23.1% | €0.0060 | €0.0150 | €0.0060 | 14,000 | |
| €0.0130 | +0.0050 | +62.5% | €0.0050 | €0.0130 | €0.0050 | 1,554 | |
| €0.0080 | +0.0010 | +14.3% | €0.0050 | €0.0080 | €0.0050 | 0 |
Splits
1 split · FWB:PGO0 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-1000 | Consolidation |
- Ticker
- Frankfurt:PGO0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 17, 2026
Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6
Latest news
Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6
Sep 17, 2026
Closed €0.01 (-9.1%) on Sep 18, 2026
Prostatype Genomics receives commitments and letters of intent of approx. 70 percent of the exercise of warrants TO6
Aug 31, 2026
Closed €0.01 (0.0%) on Aug 31, 2026
Prostatype Genomics AB resolves on a directed issue
Aug 5, 2026
Closed €0.01 (-16.7%) on Aug 6, 2026
Prostatype Genomics AB announces last day of trading in BTUs and first day of trading in warrants of series TO6 and TO7
Aug 3, 2026
Closed €0.012 (0.0%) on Aug 4, 2026
Prostatype Genomics AB announces outcome in rights issue of units
Jul 27, 2026
Closed €0.01 (0.0%) on Jul 28, 2026
Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026
Jul 21, 2026
Closed €0.011 (-8.3%) on Jul 21, 2026
The subscription period in Prostatype Genomics AB's rights issue of units begins today
Jul 9, 2026
Closed €0.012 (-25.0%) on Jul 9, 2026
Prostatype Genomics AB publishes information memorandum prior to rights issue of units
Jul 8, 2026
Closed €0.012 (-25.0%) on Jul 9, 2026
Prostatype Genomics AB enters into top-down underwriting ahead of upcoming rights issue of units
Jul 8, 2026
Closed €0.012 (-25.0%) on Jul 9, 2026
Prostatype Genomics provides financing update
Jun 30, 2026
Closed €0.025 (-10.7%) on Jul 1, 2026
Prostatype Genomics AB on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 15 in the last 12 months · 21 in all · newest Sep 17, 2026 · oldest 2025
Where Prostatype Genomics AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:PROGEN · Home listing | Stockholm | Sweden | SEK |
| OTC:PGABF | OTC | United States | USD |
| Frankfurt:PGO0 · This page | Frankfurt | Germany | EUR |
Valuation
EV/sales 13.3× against a median of 1.6×: 7th lowest of 8 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 13.48M SEK
- P/E
- Loss
- EV/sales
- 13.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.1×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Prostatype Genomics AB · OMXSTO:PROGEN | US$1.36M | US$1.32M | n/a | 13.3× | n/a | 2.1× | n/a | 0.0× | n/a |
| Telo Genomics Corp. · TSXV:TELO | US$2.80M | US$2.12M | n/a | n/a | n/a | n/a | n/a | n/a | 0.04 |
| Advanced Biomed Inc. · NASDAQ:ADVB | US$2.73M | US$3.12M | 0.5× | 12.2× | n/a | 0.2× | n/a | 0.1× | 0.35 |
| Innovotech Inc. · TSXV:IOT | US$2.66M | US$2.51M | n/a | 1.0× | n/a | 1.5× | −21.1% | 0.1× | 0.39 |
| Qlife Holding AB · OMXSTO:QLIFE | US$2.49M | US$2.88M | n/a | 34.1× | n/a | 9.6× | n/a | 3.1× | n/a |
| Physiomics PLC · LSE:PYC | US$2.46M | US$1.91M | n/a | 1.6× | n/a | 3.6× | −74.1% | 0.0× | n/a |
| 20/20 BioLabs, Inc. · NASDAQ:AIDX | US$2.10M | −US$1.01M | n/a | −0.5× | n/a | 3.4× | −317.8% | 0.9× | 1.41 |
| Bluejay Diagnostics, Inc. · NASDAQ:BJDX | US$1.90M | −US$5.43M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.71 |
| Accustem Sciences Inc · OTC:ACUT | US$1.90M | US$1.88M | n/a | n/a | n/a | n/a | n/a | n/a | 0.19 |
| InVitro International · OTC:IVRO | US$1.87M | US$644,260 | 29.6× | 0.8× | 14.0× | 1.1× | 8.2% | 0.0× | 0.17 |
| Co-Diagnostics, Inc. · NASDAQ:CODX | US$1.36M | US$2.21M | n/a | 2.6× | n/a | 0.1× | n/a | 0.2× | 2.16 |
| Median of the others | US$2.28M | US$2.02M | 15.1× | 1.6× | 14.0× | 1.3× | −47.6% | 0.1× | 0.37 |
Team and board
Officers
| Officer | Role |
|---|---|
| Fredrik Rickman | CEO Prostatype Genomics AB |
Board
| Director | Role |
|---|---|
| Anders Liljeblad | Chariman of the Board |
| Anders Lundberg | Board member |
| Håkan Englund | Board Member |
| Jörgen Dahlström | Board member |
| Mattias Prage | Board Member |
| Michael Häggman | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 17, 2023 · Before open | −10.2% |
| Q1 2023 | May 31, 2023 · Before open | +7.2% |
| Q4 2022 | Feb 16, 2023 · Before open | −1.6% |
| Q3 2022 | Nov 10, 2022 · Before open | +0.5% |
| Q2 2022 | Aug 18, 2022 · Before open | −2.5% |
| Q1 2022 | May 12, 2022 · Before open | −3.1% |
| Q4 2021 | Feb 24, 2022 · Before open | −22.1% |
| Quarter to Mar 31, 2021 | May 27, 2021 | −1.4% |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| New shares through exercise of warrants of series TO6 Closed: SEK 12.5M raised · SEK 0.1 a share · Vator Securities AB +2 Dealers: Vator Securities AB, Navia Corporate Finance AB, Birchtree Advisory AB Buyers: Vator Securities AB (8,156,289 shares at SEK 0.10 in the Directed Share Issue (underwriting and compensation shares)) Insiders: Letters of intent from the Board of Directors, management and other warrant holders corresponding to approximately SEK 2.27 million Use of proceeds: Liquidity and financial position of the company | Sep 17, 2026 | US$1.27M |
| Rights offering of units (shares and warrants of series TO6 and TO7) Closed: SEK 47.4M raised · SEK 0.1 a unit · Warrants at SEK 0.1 · Navia Corporate Finance AB +2 Dealers: Navia Corporate Finance AB (co-lead), Birchtree Advisory AB (co-lead), Vator Securities AB Insiders: Subscription commitments from existing major shareholders, including members of the Board of Directors, totalling approximately SEK 9.2 million Use of proceeds: Accelerate commercialization of Prostatype, strengthen presence in prioritized markets and continue company development | Aug 3, 2026 | US$4.88M |
| Rights offering of units (shares and two series of warrants) Update: about SEK 47.4M · SEK 0.8 a unit · Warrants at SEK 0.1 · Navia Corporate Finance AB +2 Dealers: Navia Corporate Finance AB (co-lead), Birchtree Advisory AB (co-lead), Vator Securities AB Insiders: Subscription commitments from existing major shareholders, including members of the Board of Directors, of approximately SEK 9.2 million in aggregate Use of proceeds: Continued Medicare reimbursement approval process and commercialization in the US and Europe, plus general corporate purposes | Jun 30, 2026 | US$4.88M |
| Warrant exercise of warrants of series TO5 Closed: SEK 11.5M raised · SEK 0.52 a share · Navia Corporate Finance AB +2 Dealers: Navia Corporate Finance AB, Gemstone Capital ApS, Nordic Issuing AB Buyers: Tony Chouha (1 696 784 shares in the Directed Issue as underwriter); Ghanem Chouha (1 696 784 shares in the Directed Issue as underwriter) Insiders: Pre-subscription commitments of approximately 22.2 percent (SEK 2.6 million) from board members and an existing warrant holder | Sep 18, 2025 | US$1.23M |
| Rights offering of units of new shares and warrants of series TO5 Closed: SEK 27.3M raised · One warrant of series TO5 gives the right to subscribe for one new share from 3… · Navia Corporate Finance AB +2 Dealers: Navia Corporate Finance AB (co-lead), Gemstone Capital ApS (co-lead), Nordic Issuing AB Buyers: Gerald Andriole (set-off of accumulated net remuneration of approximately SEK 2.1 million) | Jun 19, 2025 | US$2.86M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 594.0K | 199.0K | 1.36M | 683.0K | 10.0K | 683.9K | 74.1K | 161.8K | 56.0K | |
| Cost of revenue | 38.2M | -1.72M | -2.37M | 13.5M | -2.50M | 14.9M | 6.69M | -4.66M | 4.97M | |
| Gross profit | -37.6M | 1.92M | 3.73M | 683.0K | 2.51M | -14.2M | -6.61M | 4.82M | -4.91M | |
| Research and development | 1.46M | 2.21M | 3.23M | 3.51M | 1.49M | 2.41M | 1.25M | 2.52M | 2.06M | |
| Selling, general and administrative | 13.5M | 8.49M | 5.11M | 6.49M | ||||||
| Operating income | -39.1M | -40.9M | -39.2M | -28.7M | -15.5M | -16.6M | -7.86M | -9.16M | -4.63M | |
| Depreciation and amortization | 2.19M | 1.98M | 1.88M | 1.90M | 88.5K | 149.1K | 104.8K | 154.1K | 194.6K | 106.5K |
| EBITDA | -36.9M | -38.9M | -37.4M | -26.8M | -15.5M | -16.5M | -7.71M | -8.97M | -4.52M | |
| Interest expense | 1.61M | 1.68M | 1.54M | 397.0K | 81.5K | 1.49M | 0 | 684.2K | 156.9K | 0 |
| Income before tax | -44.5M | -41.1M | -41.4M | -29.1M | -15.6M | -17.4M | -8.55M | -9.32M | -4.75M | |
| Income tax | 1.71M | 1.68M | -148.1K | -2 | -7.00K | 3.08K | ||||
| Net income | -44.5M | -41.1M | -41.4M | -29.1M | -15.6M | -17.4M | -8.55M | -9.32M | -4.75M | |
| Earnings per share, basic | -1.32 | -13.67 | -12.04 | -7.72 | -10.64 | -25.16 | -613.49 | -100.94 | -0.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 9.07M | 9.42M | 2.68M | 4.81M | 9.83M | 15.9M | 2.69M | 8.21M | 10.5M | |
| Short-term investments | 21.5M | 6.68M | 10.5M | |||||||
| Receivables | 1.50M | 1.78M | 1.53M | 2.50M | 1.07M | 1.20M | 331.8K | 1.12M | 892.8K | 246.5K |
| Inventory | 78.0K | 95.0K | 203.0K | 44.0K | 107.5K | 394.9K | 387.8K | 664.0K | 376.0K | 347.4K |
| Current assets | 10.6M | 11.8M | 25.9M | 14.2M | 21.6M | 17.5M | 9.44M | 4.48M | 9.70M | 11.2M |
| Property, plant and equipment | 3.60K | 14.1K | 28.2K | 35.3K | 39.5K | 92.3K | 212.6K | |||
| Total assets | 50.9M | 42.0M | 49.2M | 30.9M | 40.2M | 33.7M | 17.6M | 19.7M | 19.7M | |
| Accounts payable | 2.73M | 2.52M | 9.45M | 2.18M | 1.17M | 1.78M | 962.2K | 652.5K | 1.18M | 996.9K |
| Current liabilities | 24.3M | 8.50M | 24.5M | 4.33M | 3.43M | 4.31M | 14.5M | 2.58M | 3.94M | 2.76M |
| Long-term debt | 0 | 0 | 67.0K | 466.7K | 866.7K | 6.45M | 9.55M | |||
| Total debt | 5.30M | 67.0K | 11.7M | 867.0K | 1.27M | 1.47M | 6.85M | 9.58M | 2.09M | |
| Total liabilities | 24.3M | 8.50M | 24.5M | 4.80M | 4.30M | 5.37M | 9.03M | 13.5M | 4.79M | |
| Shareholders' equity | 26.5M | 33.5M | 24.7M | 26.2M | 35.9M | 28.3M | 8.55M | 6.22M | 14.9M | |
| Shares outstanding | 33.8M | 3.00M | 3.44M | 3.77M | 1.47M | 691.9K | 13.9K | 92.3K | 28.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.8M | -44.7M | -29.1M | -27.7M | -16.1M | -14.7M | -7.25M | -9.63M | -5.71M | -9.63M |
| Capital spending | -258.0K | -7.86M | -8.56M | -2 | -2.50M | -26.2K | -26.2K | -3.26M | -4.66M | -27.0K |
| Free cash flow | -24.1M | -52.6M | -37.7M | -27.7M | -18.6M | -14.7M | -7.27M | -12.9M | -10.4M | -9.66M |
| Cash from investing | -13.4M | -8.36M | -8.57M | -2.50M | -3.26M | -2.16M | -3.26M | -4.66M | -3.26M | |
| Cash from financing | 36.8M | 59.8M | 28.9M | 18.9M | 23.0M | 31.1M | 15.3M | 7.38M | 8.10M | 7.38M |
| Change in cash | -352.0K | 6.74M | -8.81M | -8.84M | 4.47M | 13.2M | 5.91M | -5.52M | -2.27M | -5.52M |
Cap table
Built by 6ix from Prostatype Genomics AB’s releases · as of Sep 17, 2026
- Common shares
- 155,568,392
- Fully diluted
- 182,909,244
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 155,568,392 | Sep 17, 2026 |
| Warrants | 27,340,852 | Jun 5, 2025 |
Warrants and options
| Lot |
|---|
| Warrants · 0.10 SEK · expiry not stated |
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Sep 17, 2026 | 155,568,392 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anders Liljeblad | Chariman of the Board · Since at least Nov 5, 2026 |
| Anders Lundberg | Board member · Since at least Nov 5, 2026 |
| Fredrik Rickman | CEO Prostatype Genomics AB · Since at least Sep 17, 2026 |
| Håkan Englund | Board Member · Since at least Nov 5, 2026 |
| Jörgen Dahlström | Board member · Since at least Nov 5, 2026 |
| Mattias Prage | Board Member · Since at least Nov 5, 2026 |
| Michael Häggman | Board Member · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Prostatype Genomics AB.